| |
CMS-H001 is targeted at the treatment of helicobacter pylori
(HP)-induced gastritis and peptic ulcer, which is currently
in pre-clinical research stage.
CMS-H001 has acquired initial pharmacodynamics verification
and the Group is in the process of applying for patent protection.
It is scheduled to complete its preclinical study and commence
Phase I clinical trials in 2008. |
|
|